Cargando…
Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial
BACKGROUND: Complex abdominal wall reconstruction technique remains controversial. The use of biologic mesh products is also debated in active infection, sepsis prophylaxis and high-risk patients. Differences in biologic mesh technology and cost remain significant. We aimed to compare the efficacy o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377544/ https://www.ncbi.nlm.nih.gov/pubmed/35961662 http://dx.doi.org/10.1503/cjs.020621 |
_version_ | 1784768360138932224 |
---|---|
author | Ball, Chad G. Kirkpatrick, Andrew W. Stuleanu, Tommy Rosen, Michael J. Eberle, Tammy L. |
author_facet | Ball, Chad G. Kirkpatrick, Andrew W. Stuleanu, Tommy Rosen, Michael J. Eberle, Tammy L. |
author_sort | Ball, Chad G. |
collection | PubMed |
description | BACKGROUND: Complex abdominal wall reconstruction technique remains controversial. The use of biologic mesh products is also debated in active infection, sepsis prophylaxis and high-risk patients. Differences in biologic mesh technology and cost remain significant. We aimed to compare the efficacy of 2 commonly used biologic meshes in regards to hernia recurrence at 1 year. METHODS: This study was a parallel, dual-arm, double-blind randomized controlled trial involving adult patients undergoing complex abdominal wall reconstruction with a biologic mesh at a quaternary care institution (2017–2020). Patients were randomly assigned to receive Permacol (cross-linked) compared with Strattice (not crosslinked). The main outcome measure was hernia recurrence at 1 or more years following the index repair. RESULTS: We included 94 patients randomized to undergo reconstruction with 1 of 2 commonly used biologic mesh products (mean age 59.4 yr, standard deviation [SD] 9.9; 51% female; body mass index 32.9, SD 6.8). We found no significant differences between the groups (patient comorbidities, hernia recurrence risk factors, hernia size or infection profiles). Hernia recurrence rates (15%) were similar between groups (median 783 days of follow up, interquartile range 119). We found there was significantly less of a need for a component separation technique in the Strattice group (69% v. 87%). All other secondary outcome measures were equivalent between study arms. Multivariate analysis identified hepatic transplantation (odds ratio [OR] 1.94, 95% confidence intervals [CI] 0.33–4.41), active abdominal wall infection (OR 2.01, 95% CI 0.50–7.01), and more than 1 previous hernia repair (OR 2.68, 95% CI 0.41–5.99) as risk factors for subsequent hernia recurrence; however, there was no difference in recurrence factors between patient study groups. CONCLUSION: Given similar clinical performance between the 2 most commonly used biologic mesh products, the most cost effective mesh should be used in cost-conscious health care systems. |
format | Online Article Text |
id | pubmed-9377544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | CMA Impact Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93775442022-08-21 Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial Ball, Chad G. Kirkpatrick, Andrew W. Stuleanu, Tommy Rosen, Michael J. Eberle, Tammy L. Can J Surg Research BACKGROUND: Complex abdominal wall reconstruction technique remains controversial. The use of biologic mesh products is also debated in active infection, sepsis prophylaxis and high-risk patients. Differences in biologic mesh technology and cost remain significant. We aimed to compare the efficacy of 2 commonly used biologic meshes in regards to hernia recurrence at 1 year. METHODS: This study was a parallel, dual-arm, double-blind randomized controlled trial involving adult patients undergoing complex abdominal wall reconstruction with a biologic mesh at a quaternary care institution (2017–2020). Patients were randomly assigned to receive Permacol (cross-linked) compared with Strattice (not crosslinked). The main outcome measure was hernia recurrence at 1 or more years following the index repair. RESULTS: We included 94 patients randomized to undergo reconstruction with 1 of 2 commonly used biologic mesh products (mean age 59.4 yr, standard deviation [SD] 9.9; 51% female; body mass index 32.9, SD 6.8). We found no significant differences between the groups (patient comorbidities, hernia recurrence risk factors, hernia size or infection profiles). Hernia recurrence rates (15%) were similar between groups (median 783 days of follow up, interquartile range 119). We found there was significantly less of a need for a component separation technique in the Strattice group (69% v. 87%). All other secondary outcome measures were equivalent between study arms. Multivariate analysis identified hepatic transplantation (odds ratio [OR] 1.94, 95% confidence intervals [CI] 0.33–4.41), active abdominal wall infection (OR 2.01, 95% CI 0.50–7.01), and more than 1 previous hernia repair (OR 2.68, 95% CI 0.41–5.99) as risk factors for subsequent hernia recurrence; however, there was no difference in recurrence factors between patient study groups. CONCLUSION: Given similar clinical performance between the 2 most commonly used biologic mesh products, the most cost effective mesh should be used in cost-conscious health care systems. CMA Impact Inc. 2022-08-12 /pmc/articles/PMC9377544/ /pubmed/35961662 http://dx.doi.org/10.1503/cjs.020621 Text en © 2022 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Research Ball, Chad G. Kirkpatrick, Andrew W. Stuleanu, Tommy Rosen, Michael J. Eberle, Tammy L. Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title | Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title_full | Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title_fullStr | Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title_full_unstemmed | Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title_short | Is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? A randomized controlled trial |
title_sort | is the type of biomesh relevant in the prevention of recurrence following abdominal wall reconstruction? a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377544/ https://www.ncbi.nlm.nih.gov/pubmed/35961662 http://dx.doi.org/10.1503/cjs.020621 |
work_keys_str_mv | AT ballchadg isthetypeofbiomeshrelevantinthepreventionofrecurrencefollowingabdominalwallreconstructionarandomizedcontrolledtrial AT kirkpatrickandreww isthetypeofbiomeshrelevantinthepreventionofrecurrencefollowingabdominalwallreconstructionarandomizedcontrolledtrial AT stuleanutommy isthetypeofbiomeshrelevantinthepreventionofrecurrencefollowingabdominalwallreconstructionarandomizedcontrolledtrial AT rosenmichaelj isthetypeofbiomeshrelevantinthepreventionofrecurrencefollowingabdominalwallreconstructionarandomizedcontrolledtrial AT eberletammyl isthetypeofbiomeshrelevantinthepreventionofrecurrencefollowingabdominalwallreconstructionarandomizedcontrolledtrial |